# E4A Dupixent Business Partner Respiratory Diseases at Sanofi

Sanofi is hiring an E4A Dupixent Business Partner Respiratory Diseases in Cambridge, United States. It pays $179k-$258k a year and Level rates it Little AI ●○○○; you can [apply on Sanofi](https://jobsbylevel.com/go/570dd4bc-0a65-48c8-9f8c-3dd0b42bad9f?utm_medium=ai-agent).

AI Level 1, AI centrality 0 out of 100. Cambridge, MA.

## Details

- Company: [Sanofi](https://jobsbylevel.com/companies/sanofi)
- AI level: AI Level 1 (score 0 out of 100)
- Location: Cambridge, MA
- Salary: $179k-$258k
- Posted: September 29, 2026
- Apply: https://jobsbylevel.com/go/570dd4bc-0a65-48c8-9f8c-3dd0b42bad9f?utm_medium=ai-agent
- Free CV review for this job: https://jobsbylevel.com/cv-review?job=e4a-dupixent-business-partner-respiratory-diseases-at-sanofi-2af730

## Prepare for this job

The job page lists 4 likely interview questions for this offer, with a CV checklist: https://jobsbylevel.com/jobs/e4a-dupixent-business-partner-respiratory-diseases-at-sanofi-2af730

## Description

Job title : E4A Dupixent Business Partner Respiratory Diseases Location: Cambridge, MA or Morristown, NJ About the Job Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Dupixent (dupilumab) represents one of the most significant advances in the treatment of Type 2 inflammatory diseases in a generation. As a first-in-class biologic targeting the IL-4/IL-13 pathway, Dupixent has transformed the standard of care for patients living with moderate-to-severe asthma and, most recently, Chronic Obstructive Pulmonary Disease (COPD) — becoming the first biologic approved for COPD with a Type 2 inflammatory phenotype. Sanofi is committed to maximizing the full potential of Dupixent across the respiratory space, building a robust and differentiated evidence base that demonstrates its transformative value to patients, payers, and health systems. Through a focused and rapidly expanding body of clinical and real-world evidence, Sanofi aims to address critical gaps in care and deliver meaningful, potentially life-changing treatment options for the millions of patients living with Type 2 inflammatory respiratory conditions who continue to face significant unmet need. This role is primarily focused on Dupixent in COPD and Asthma. Depending on business need, the incumbent may also be called upon to support evidence generation activities for other assets within the respiratory or broader Sanofi portfolio. Evidence for Access (E4A) Vision, Mission, and Values We are one bold HEOR team leveraging innovative HEOR to transform patient care and access. As HEOR experts, we lead the generation and dissemination of robust, business-relevant evidence to demonstrate value and drive access to medicines. The E4A organization is driven by five core values that define how we work and deliver impact. We operate as One Team , partnering without boundaries while pursuing a Bold Purpose through ambitious, measurable goals. Grounded in Scientific Excellence with Relevance and deep technical expertise, we embrace Innovation in Action to transform how we research and deliver Impact for People , creating meaningful outcomes for patients, the healthcare ecosystem, and our colleagues who make it all possible. This role is accountable for leading US HEOR strategy and execution for Dupixent in respiratory disease — with a primary focus on COPD and Asthma — serving as the primary US E4A point of contact for the portfolio and partnering cross-functionally to drive the generation, translation, and dissemination of high-quality, decision-relevant evidence to support access in the United States. The role sits at the heart of one of Sanofi's most strategically significant and commercially important portfolios, requiring a combination of deep scientific expertise in respiratory disease and Type 2 inflammation, strategic thinking, and a sophisticated understanding of the US payer and market access landscape. You will work in the Dupixent Respiratory team of the Evidence for Access (E4A) department. The E4A department gathers a wealth of expertise including experts in Health Economic and Outcomes Research (HEOR), Indirect Treatment Comparison & Network Meta-Analysis (ITC/NMA), Modelling, Health Technology Assessment (HTA), Evidence Synthesis, Epidemiology, Biostatistics, and generation of Real-World Evidence (RWE). Within E4A Dupixent Respiratory, you will join a team responsible for E4A projects across

The description is cut here. Read the full offer: https://jobsbylevel.com/jobs/e4a-dupixent-business-partner-respiratory-diseases-at-sanofi-2af730

Source: https://jobsbylevel.com/jobs/e4a-dupixent-business-partner-respiratory-diseases-at-sanofi-2af730

## Cite this page

Level. https://jobsbylevel.com/jobs/e4a-dupixent-business-partner-respiratory-diseases-at-sanofi-2af730.

Get job alerts: https://jobsbylevel.com/newsletter